Ethambutol 400 mg film-coated tablets
Each film-coated tablet contains 400 mg of Ethambutol hydrochloride.
For the full list of excipients, see section 6.1.
Grey, circular, biconvex, coated tablets plain on both sides with an approximate diameter of 12.60 mm.
The primary treatment and re-treatment of tuberculosis and for prophylaxis in cases of inactive tuberculosis or large tuberculin positive reaction. Ethambutol should only be used in conjunction with other anti-tuberculous drugs to which the patient's organisms are susceptible.
The dosage of Ethambutol must be adjusted according to the body weight of the patient.
For primary treatment and prophylaxis: Ethambutol should be administered in a single daily oral dose of 15mg/kg, concomitant drugs being maintained at their recommended dosage levels.
For re-treatment: For the first 60 days of treatment, Ethambutol should be administered in a single daily oral dose of 25mg/kg. Thereafter the dosage should be reduced to 15mg/kg, concomitant drugs being maintained at their recommended dosage levels.
For primary treatment and re-treatment: For the first 60 days of treatment, a single daily oral dose of 25mg/kg. Thereafter the dosage should be reduced to 15mg/kg, concomitant drugs being maintained at their recommended dosage levels.
For prophylaxis: A single daily oral dose of 15mg/kg, concomitant drugs being used at their recommended dosage levels.
As for adults: However, patients with decreased renal function may need to have the dosage adjusted as determined by blood levels of Ethambutol.
In order to obtain maximum effect due to high serum levels, drug administration should be once daily.
Renal function should be checked before treatment with antituberculous drugs and appropriate dosage adjustments made. Ethambutol should preferably be avoided in patients with renal impairment
If used, where creatinine clearance is less than 30mL/minute, use 15–25 mg/kg (max. 2.5 g) 3 times a week and plasma Ethambutol concentration should be monitored.
Method of administration: Oral
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
It is also contra-indicated in patients with known optic neuritis and poor vision unless clinical judgement determines that it may be used.
Toxic effects are more common if renal function is impaired.
Ethambutol may produce a unique type of visual impairment which is generally reversible and which appears to be due to optic neuritis and to be related to dose and duration of treatment.
Less than 1% of patients undergoing treatment with the higher dose regimen of 25mg/kg/day for two months, and 15mg/kg/day thereafter, have exhibited decrease in visual acuity. It is recommended that patients undergo a full ophthalmic examination before starting treatment. This should include visual acuity, colour vision, perimetry and ophthalmoscopy. Any change may be unilateral or bilateral and hence both eyes should be tested individually.
Routine ophthalmological examination for adults is not thereafter necessary, but patients should be informed the importance of reporting any change in vision.
Routine ophthalmological examinations may be considered desirable when treating young children.
Any negative effects on vision are generally reversible when administration of the drug is discontinued promptly and recovery of visual acuity has usually occurred over a period of weeks to months after the drug was discontinued. Patients have then received Ethambutol at lower dosages without toxicity.
In rare cases, recovery may be delayed for up to one year or more or the effects may be irreversible.
Liver function tests should be performed in patients who develop symptoms suggestive of hepatitis or who become generally unwell during treatment.
Consideration should be given to current clinical guidance on the appropriate use of antituberculous drugs.
Aluminium hydroxide may impair the absorption of Ethambutol. Therefore antacids containing this ingredient should be avoided during treatment with Ethambutol.
There are no or limited data from the use of Ethambutol in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown.
Ethambutol is not recommended during pregnancy and in women of childbearing potential unless the potential benefit to the mother is considered to outweigh any possible risks.
Ethambutol/metabolites have been identified in breastfed newborns/infants of treated women. There is insufficient information on the effects of Ethambutol in newborns/infants.
Breast-feeding is not recommended during Ethambutol treatment unless the benefit of breast-feeding to the child is considered to outweigh any possible risks.
Patients who suffer from visual impairment during treatment with Ethambutol should not drive or operate machinery.
Numbness, paraesthesia, dizziness, disorientation are also among possible side effects that may affect a patient's ability to drive or operate machinery, if affected, patients should not drive or operate machinery.
In this section, frequencies of undesirable effects are defined as follows: Frequency: very common (>1/10); common (>1/100, <1/10); uncommon (>1/1,000, <1/100); rare (>1/10,000, <1/1,000), very rare (<1/10,000).
Blood & lymphatic system disorders:
Very rare: Leucopenia, neutropenia
Immune system disorders:
Very rare: Hypersensitivity, anaphylactoid reactions, (see also Skin and subcutaneous tissue disorders)
Metabolic & nutrition disorders:
Very rare: Gout
Nervous system disorders:
Rare: Peripheral neuropathy, numbness, paraesthesia of the extremities
Very rare: headache, dizziness, disorientation
Very rare: mental confusion, hallucinations
Uncommon: Optic neuritis (decreased visual acuity, loss of vision, scotoma, colour blindness, visual disturbance, visual field defect, eye pain)
Respiratory, thoracic & mediastinal disorders:
Very rare: Pneumonitis, pulmonary infiltrates, with or without eosinophilia
Gastrointestinal disorders such as anorexia, nausea, vomiting, abdominal pain and diarrhoea have been noted in patients on multiple drug anti-tuberculosis therapy including Ethambutol although not in test patients receiving Ethambutol as sole therapy.
Hepatic reactions with hepatitis, jaundice, abnormal liver function test values, and very rarely, hepatic failure, have been reported in patients treated with multiple drug therapy including Ethambutol. Liver function tests should be performed in patients who develop symptoms suggestive of hepatitis or who become generally unwell during treatment.
Skin & subcutaneous tissue disorders:
Rare: Rash, pruritus, urticaria
Very rare: photosensitive lichenoid eruptions, bullous dermatitis, Stevens-Johnson syndrome, epidermal necrolysis
Musculoskeletal and connective tissue disorders:
Very rare: Joint pains
Renal & urinary disorders
Very rare: Interstitial nephritis
General disorders and administration site conditions:
Very rare: Malaise, pyrexia
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms: Gastrointestinal disturbances, vomiting, fever, headache, anorexia, dizziness, hallucinations and/or visual disturbances.
Management: No specific antidote, but gastric lavage should be employed if necessary.
Pharmacotherapeutic group: Antimycobacterial, ATC code: J04AK02.
Ethambutol is bacteriostatic. It is effective against Mycobacterium tuberculosis and M. bovis with an MIC of 0.5 - 8 μg per ml. While it has activity against some atypical mycobacteria including M. Kansarii, activity against other micro-organisms has not yet been reported.
It is effective against tubercle bacilli resistant to other tuberculostatics. Cross-resistance has not yet been reported.
Primary resistance to Ethambutol is uncommon but resistant strains of M. tuberculosis are readily produced if Ethambutol is used alone.
Ethambutol is readily absorbed after oral administration and this absorption is not significantly impaired by food. After a single dose of 25mg/kg body weight, within 4 hours peak plasma concentrations of up to 5μg/ml are obtained, by 24 hours the concentration decreases to less than 1μg/ml.
Ethambutol readily diffuses into red blood cells and into the cerebrospinal fluid when the meninges are inflamed. It has also been reported to cross the placenta.
Most of a dose is excreted unchanged in the urine and up to 20% in faeces, within 48 hours. From 8 - 15% of a dose appears in urine as inactive metabolites.
Nothing further of relevance to prescriber.
Colloidal anhydrous silica
Polyvinyl alcohol-part. hydrolyzed
Mono and diglycerides
Sodium lauryl sulphate
Black iron oxide
Brilliant blue FCF aluminum lake
After first opening the plastic container: 60 days
Do not store above 25°C.
Ethambutol Tablets are available in Alu-Alu blister, Alu-PVC/PE/PVdC blister and HDPE container with polypropylene cap.
10, 14, 20, 28, 30, 56, 60, 84, 90, 100 and 112 tablets in blister pack (Alu-Alu)
10, 14, 20, 28, 30, 56, 60, 84, 90, 100 and 112 tablets in blister pack (Alu-PVC/PE/PVdC)
1000 tablets in HDPE container with polypropylene cap
Not all pack sizes may be marketed.
Brown & Burk UK Limited
5, Marryat Close,
Middlesex TW4 5DQ